List view / Grid view
Researchers have shown that histones are vital in silencing genes and that their position is inherited in new cells, providing insight into how cancer cells can become resistant to therapy.
A team has imaged the process that the body uses to stabilise DNA, which could be used to develop therapies for conditions such as cancer.
Researchers have discovered a microprotein that acts as a regulator of cell stress, which could be used in developing therapies for a wide range of conditions.
A new study has discovered two enzymes which regulate a biological switch that controls the immune system, providing the potential to develop targeted therapies.
A new study has shown the specific cellular mechanisms that limit the ability of CD8 T cells to infiltrate the tumour microenvironment, which could guide new immunotherapeutic strategies in cancer.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
Regulator genes and proteins have been identified on circulating tumour cells in mice which allow them to target other organs in the body.
A new mechanism by which cancer cells become resistant to chemotherapy has been found which could lead to a new target for drugs.
A new study into the enzyme Cdc34 may make it possible to target the enzyme specifically to develop new cancer therapeutics.
A therapy has been developed which uses a synthetic RNA molecule developed to fight viruses to trigger an immune response against tumours in mice.
A study has found a selective inhibitor for an enzyme that allows cancer cells to mutate and become resistant to treatments.
A team has used viral gene editing and CRISPR to form a system that marks tumours for destruction, potentially improving immunotherapies.
A new algorithm has been developed which personalises which cancer mutations are best targets for immunotherapy.
New protein-painting technology could lead to developing cancer immunotherapy medicines that can be administered as a pill.
The researcher Sir Peter Ratcliffe and two others have been jointly awarded the Nobel Prize for Physiology or Medicine 2019.
